Veeva Systems/$VEEV
1D1W1MYTD1Y5YMAX
Capital at risk
About Veeva Systems
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
- Ticker
- $VEEV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 7,928
- Headquarters
- Pleasanton, United States
- Website
- www.veeva.com
Veeva Systems Metrics
BasicAdvanced
$43B
43.55
$6.10
0.97
-
Price and volume
Market cap
$43B
Beta
0.97
52-week high
$310.50
52-week low
$148.05
Average daily volume
1.8M
Financial strength
Current ratio
5.458
Quick ratio
5.363
Long term debt to equity
0.018
Total debt to equity
0.02
Profitability
EBITDA (TTM)
1,075.341
Gross margin (TTM)
74.96%
Net profit margin (TTM)
29.34%
Operating margin (TTM)
29.93%
Effective tax rate (TTM)
23.55%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
7.58%
Return on equity (TTM)
14.42%
Valuation
Price to earnings (TTM)
43.553
Price to revenue (TTM)
12.563
Price to book
5.8
Price to tangible book (TTM)
6.27
Price to free cash flow (TTM)
26.509
Free cash flow yield (TTM)
3.77%
Free cash flow per share (TTM)
10.022
Growth
Revenue change (TTM)
16.50%
Earnings per share change (TTM)
25.52%
3-year revenue growth (CAGR)
15.71%
10-year revenue growth (CAGR)
22.03%
3-year earnings per share growth (CAGR)
22.48%
10-year earnings per share growth (CAGR)
32.35%
What the Analysts think about Veeva Systems
Analyst ratings (Buy, Hold, Sell) for Veeva Systems stock.
Analyst projections of the future price of Veeva Systems stock.
Bulls say / Bears say
Fiscal Q2 FY2027 revenue of $927.963 million surpassed the IBES consensus of $905.3 million, underscoring sustained demand growth in Veeva’s core life sciences cloud offerings. (Reuters)
Vault CRM expansion drove Q2 results to top estimates, reflecting accelerated adoption among large pharmaceutical clients and validating Veeva’s product strategy. (Reuters)
Inclusion in the S&P 500 effective May 7 led to a 10.3% premarket share surge, boosting index fund inflows and broadening institutional ownership. (Reuters)
Citi downgraded Veeva to ‘neutral’ from ‘buy’ and cut its price target to $176, warning that 2026 may be a “relatively inconsequential year” and raising the risk of further multiple de-ratings. (Reuters)
Citi cautioned that subscription revenue could dip below 20% for the first time this year, signaling potential slowdown in Veeva’s high-margin recurring revenue growth. (Reuters)
Citi forecast limited margin expansion or slight contraction as Veeva ramps R&D and absorbs higher AI-related costs, pressuring near-term profitability. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 27 Aug 2026.
Veeva Systems Financial Performance
Revenues and expenses
Veeva Systems Earnings Performance
Company profitability
Upcoming events
No upcoming events
Veeva Systems News
AllArticlesVideos
Funds containing Veeva Systems
AllEURGBPUSD
Fund name | Fund size | $VEEV weighting |
|---|---|---|
VanEck Morningstar Wide Moat€GMVM | €407M | 3.24% |
VanEck Morningstar Wide Moat£MOGB | £354M | 3.24% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.97% |
Amundi S&P 500£500G | £6.6B | 0.67% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.50% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.